Rami Rahal, Ph.D., is a Partner at MPM BioImpact where he is responsible for investment identification and due diligence of public biotechnology companies. Rami has spent the majority of his career advancing precision oncology and immunotherapy medicines, including Gavreto, an FDA approved therapy for metastatic, RET-driven, non-small cell lung cancer and advanced thyroid cancers. Prior to joining MPM BioImpact in 2022, Rami was a Senior Director of Cancer Biology at Scorpion Therapeutics where he joined as the first biologist and played pivotal roles in expanding the biology drug discovery team, research infrastructure, and early portfolio. Rami originally trained as a geneticist at Massachusetts Institute of Technology and conducted postdoctoral fellowships at Harvard Medical School and the Novartis Institutes for Biomedical Research. His research has been published in Nature Medicine and highlighted in Cancer Cell, Cancer Discovery, and Nature Reviews Cancer.